文献速递复苏、休克与脓毒症心脑血管急症

胺碘酮与利多卡因治疗院内心脏骤停的疗效比较

Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest.
PubMed 文献 · Chest · 2022-11-02
一句话结论院内心室颤动/室性心动过速心脏骤停中,利多卡因相较胺碘酮与更高的自主循环恢复、24小时生存、出院生存及良好神经预后相关。

这项回顾性队列研究纳入2000年1月1日至2014年12月31日期间美国心脏协会Get With the Guidelines-Resuscitation(GWTG-R)参与医院中,因室性心动过速/心室颤动(VT/VF)发生院内心脏骤停且对心肺复苏和除颤无效的成人患者,比较胺碘酮与利多卡因治疗与结局的关系。共14,630例患者,68.7%(n=10,058)接受胺碘酮,31.3%(n=4,572)接受利多卡因。校正所有协变量后,利多卡因相较胺碘酮与更高的自主循环恢复(AOR 1.15,P=.01)、24小时生存(AOR 1.16,P=.004)、出院生存(AOR 1.19,P<.001)和出院时良好神经预后(AOR 1.18,P<.001)相关。倾向性评分方法结果与多变量逻辑回归分析相似。

要点

  • 在院内心室颤动/室性心动过速心脏骤停且对心肺复苏和除颤无效的成人患者中,利多卡因相较胺碘酮与更高的自主循环恢复几率相关(AOR 1.15,P=.01)。
  • 利多卡因相较胺碘酮与更高的24小时生存几率相关(AOR 1.16,P=.004)。
  • 利多卡因相较胺碘酮与更高的出院生存几率相关(AOR 1.19,P<.001)。
  • 利多卡因相较胺碘酮与更高的出院时良好神经预后几率相关(AOR 1.18,P<.001)。
  • 该研究为回顾性队列研究,结果来自美国心脏协会GWTG-R参与医院,尚需前瞻性研究验证。

适用人群与场景

  • 美国心脏协会Get With the Guidelines-Resuscitation(GWTG-R)参与医院中,2000年1月1日至2014年12月31日期间因室性心动过速/心室颤动(VT/VF)发生院内心脏骤停、对心肺复苏和除颤无效的成人患者。

诊断标准与关键阈值

  • 院内心脏骤停,心律为室性心动过速/心室颤动(VT/VF),且对心肺复苏和除颤无效。

研究设计与关键结果

  • 回顾性队列研究,纳入14,630例因VT/VF发生院内心脏骤停的成人患者,其中68.7%(n=10,058)接受胺碘酮治疗,31.3%(n=4,572)接受利多卡因治疗。
  • 主要结局自主循环恢复:相较胺碘酮,利多卡因的校正比值比(AOR)为1.15(P=.01),平均边际效应(AME)为2.3(95%CI 0.5至4.2)。
  • 次要结局24小时生存:相较胺碘酮,利多卡因的AOR为1.16(P=.004),AME为3.0(95%CI 0.9至5.1)。
  • 次要结局出院生存:相较胺碘酮,利多卡因的AOR为1.19(P<.001),AME为3.3(95%CI 1.5至5.2)。
  • 次要结局出院时良好神经预后:相较胺碘酮,利多卡因的AOR为1.18(P<.001),AME为3.1(95%CI 1.3至4.9)。
  • 使用倾向性评分方法的结果与多变量逻辑回归分析结果相似。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在因VT/VF发生院内心脏骤停的成人患者中,与胺碘酮相比,利多卡因治疗与更高的自主循环恢复、24小时生存、出院生存及良好神经预后相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: American Heart Association Advanced Cardiac Life Support (ACLS) guidelines support the use of either amiodarone or lidocaine for cardiac arrest caused by ventricular tachycardia or ventricular fibrillation (VT/VF) based on studies of out-of-hospital cardiac arrest. Studies comparing amiodarone and lidocaine in adult populations with in-hospital VT/VF arrest are lacking.

RESEARCH QUESTION: Does treatment with amiodarone vs lidocaine therapy have differential associations with outcomes among adult patients with in-hospital cardiac arrest from VT/VF?

STUDY DESIGN AND METHODS: This retrospective cohort study of adult patients receiving amiodarone or lidocaine for VT/VF in-hospital cardiac arrest refractory to CPR and defibrillation between January 1, 2000, and December 31, 2014, was conducted within American Heart Association Get With the Guidelines-Resuscitation (GWTG-R) participating hospitals. The primary outcome was return of spontaneous circulation (ROSC). Secondary outcomes were 24 h survival, survival to hospital discharge, and favorable neurologic outcome.

RESULTS: Among 14,630 patients with in-hospital VT/VF arrest, 68.7% (n = 10,058) were treated with amiodarone and 31.3% (n = 4,572) with lidocaine. When all covariates were statistically controlled, compared with amiodarone, lidocaine was associated with statistically significantly higher odds of the following: (1) ROSC (adjusted OR [AOR], 1.15, P = .01; average marginal effect [AME], 2.3; 95% CI, 0.5 to 4.2); (2) 24 h survival (AOR, 1.16; P = 004; AME, 3.0; 95% CI, 0.9 to 5.1); (3) survival to discharge (AOR, 1.19; P < .001; AME, 3.3; 95% CI, 1.5 to 5.2); and (4) favorable neurologic outcome at hospital discharge (AOR, 1.18; P < .001; AME, 3.1; 95% CI, 1.3 to 4.9). Results using propensity score methods were similar to those from multivariable logistic regression analyses.

INTERPRETATION: Compared with amiodarone, lidocaine therapy among adult patients with in-hospital cardiac arrest from VT/VF was associated with statistically significantly higher rates of ROSC, 24 h survival, survival to hospital discharge, and favorable neurologic outcome.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Wagner D, Kronick SL, Nawer H, et al. Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest. Chest. 2022. PMID: 36332663. doi:10.1016/j.chest.2022.10.024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。